International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026
Nomogram for predicting HIFU efficacy in uterine fibroids: based on oxytocin-induced arterial-phase perfusion delay and ultrasound features.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Dan-Ling, Wu Songsong, Ding Guisheng, Chen XinWei, Chen Sheng
Аннотация
PURPOSE: This study aimed to develop and validate a nomogram for predicting high-intensity focused ultrasound (HIFU) ablation efficacy in uterine fibroids, based on the Oxytocin-Induced Arterial-phase Perfusion Delay Time(APDT) on contrast-enhanced ultrasound (CEUS), combined with ultrasound features.
METHODS: A retrospective analysis was performed on 53 patients (76 fibroids) who underwent oxytocin-assisted HIFU treatment. All patients underwent abdominal ultrasound before HIFU, with APDT on CEUS recorded pre- and post-oxytocin challenge. Predictive factors were identified via univariate and multivariate logistic regression analyses. A clinical efficacy prediction model for HIFU treatment was established using R software and visualized as a nomogram. Its discriminative ability, calibration performance, and clinical utility were evaluated.
RESULTS: The final predictive factors included the number of intratumoral attenuation bands, oxytocin-induced APDT, peripheral blood flow grade, and location/type of fibroids. The nomogram's calibration curve demonstrated excellent agreement between observed and predicted values (absolute error = 0.034). The discriminative ability, assessed by the area under the receiver operating characteristic curve (AUC), was 0.884 (95% CI: 0.803-0.965). The model achieved a sensitivity of 92.7% and specificity of 76.2%, indicating strong predictive value for ablation outcomes. Decision curve analysis revealed high clinical utility with a maximum net benefit threshold probability range of 0%-97%.
CONCLUSION: The HIFU ablation efficacy prediction model, integrating oxytocin-induced Arterial-phase Perfusion Delay Time and ultrasound features, demonstrated robust predictive performance and may assist clinicians in selecting suitable candidates for HIFU treatment.
METHODS: A retrospective analysis was performed on 53 patients (76 fibroids) who underwent oxytocin-assisted HIFU treatment. All patients underwent abdominal ultrasound before HIFU, with APDT on CEUS recorded pre- and post-oxytocin challenge. Predictive factors were identified via univariate and multivariate logistic regression analyses. A clinical efficacy prediction model for HIFU treatment was established using R software and visualized as a nomogram. Its discriminative ability, calibration performance, and clinical utility were evaluated.
RESULTS: The final predictive factors included the number of intratumoral attenuation bands, oxytocin-induced APDT, peripheral blood flow grade, and location/type of fibroids. The nomogram's calibration curve demonstrated excellent agreement between observed and predicted values (absolute error = 0.034). The discriminative ability, assessed by the area under the receiver operating characteristic curve (AUC), was 0.884 (95% CI: 0.803-0.965). The model achieved a sensitivity of 92.7% and specificity of 76.2%, indicating strong predictive value for ablation outcomes. Decision curve analysis revealed high clinical utility with a maximum net benefit threshold probability range of 0%-97%.
CONCLUSION: The HIFU ablation efficacy prediction model, integrating oxytocin-induced Arterial-phase Perfusion Delay Time and ultrasound features, demonstrated robust predictive performance and may assist clinicians in selecting suitable candidates for HIFU treatment.